Table 2 Overview of examinations during the BDNF trial
STUDY PERIOD | ||||||
|---|---|---|---|---|---|---|
TIMEPOINT | Screening (day 0) | Baseline (day 0-7) | Weekly examinations | Biweekly-examinations | Follow Up (day 49 +/- 3) | Follow Up by phone (day 70 +/-3) |
ENROLMENT: | ||||||
Eligibility screen | X | |||||
Informed consent | X | |||||
Allocation | X | |||||
ASSESSMENTS: | ||||||
MINI-DIPS (+ MD-DIPS) | X | |||||
Demographics (sex, age, education, employment, social network, marital status, living situation) | X | |||||
Routine blood work (HDL, LDL, Triglyceride, cholesterol, differential blood count, HbA1c (only BL), CRP, 25-OH-Vitamin D3, Vitamin B12, folate, cortisol, TSH, Insulin, Na, K, Ca, Cl, CK, eGFR, Kreatinin, GOT, GPT, gammaGT) | X | X | ||||
BDNF blood withdrawal | X | |||||
Current medication and side effects | X | X | X | X | ||
Psychotherapy | X | X | X | X | ||
Other treatment modalities | X | X | X | X | ||
BDI-II | X | X | X | X | ||
MADRS | X | X | X | X | ||
HDRS-24 | X | X | X | X | ||
DOTES | X | X | X | X | ||